Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
Not Confirmed
Not Confirmed
10-12 December, 2025
Cosmoprof IndiaCosmoprof India
Not Confirmed
Not Confirmed
04-06 December, 2025
Not Confirmed
Not Confirmed
05-09 December, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS






Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
10-12 December, 2025
Cosmoprof IndiaCosmoprof India
Industry Trade Show
Not Confirmed
04-06 December, 2025
Industry Trade Show
Not Confirmed
05-09 December, 2025
Digital content

20 Nov 2025
// FIERCE PHARMA
https://www.fiercepharma.com/pharma/pfizer-tris-pharma-ink-415m-deal-settle-adulterated-adhd-drug-allegations-texas

16 Oct 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251016627732/en/Tris-Pharma-Announces-Acceptance-of-New-Review-Article-Highlighting-Challenges-of-Treating-Moderate-to-Severe-Acute-Pain-with-Currently-Available-Drugs

28 Aug 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250828170321/en/Tris-Pharma-Showcases-a-Novel-Mechanism-of-Dual-NOPMOP-NMR-Agonism-for-the-Treatment-of-Moderate-to-Severe-Acute-Pain-and-Encores-Positive-Phase-3-Data-at-2025-Annual-PAINWeek-Meeting-in-Las-Vegas

27 Jun 2025
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219454

12 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250612665724/en/Tris-Pharma-to-Debut-Positive-Results-of-Intranasal-Snorting-Human-Abuse-Potential-Study-of-Cebranopadol-an-Investigational-First-In-Class-Oral-Dual-NMR-Agonist-for-the-Treatment-of-Moderate-to-Severe-Pain-at-the-2025-CPDD-Annual-Meeting

01 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250501204234/en/Tris-Pharma-to-Unveil-Positive-Phase-3-Results-including-a-Strong-Safety-Profile-Showcasing-the-Potential-of-Cebranopadol-an-Investigational-First-in-Class-Dual-NMR-Agonist-for-the-Treatment-of-Pain-at-the-2025-ASRA-Annual-Meeting
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
Tris Pharma Inc is a supplier offers 6 products (APIs, Excipients or Intermediates).
Find a price of Carbinoxamine bulk with DMF offered by Tris Pharma Inc
Find a price of Chlorpheniramine Maleate bulk with DMF offered by Tris Pharma Inc
Find a price of Clonidine bulk with DMF offered by Tris Pharma Inc
Find a price of Codeine bulk with DMF offered by Tris Pharma Inc
Find a price of Methylphenidate bulk with DMF offered by Tris Pharma Inc
Find a price of Sodium Oxybate bulk with DMF offered by Tris Pharma Inc